Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Kalvista Pharmaceuticals Inc (KALV) USD0.001

Sell:$14.35 Buy:$14.41 Change: $0.23 (1.63%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:$14.35
Buy:$14.41
Change: $0.23 (1.63%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:$14.35
Buy:$14.41
Change: $0.23 (1.63%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Contact details

Address:
55 Cambridge Pkwy Ste 901E
CAMBRIDGE
02142-1234
United States
Telephone:
+1 (857) 9990075
Website:
www.kalvista.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KALV
ISIN:
US4834971032
Market cap:
$266.09 million
Shares in issue:
17.83 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Crockett
    Chief Executive Officer, Director
  • Benjamin Palleiko
    Chief Financial Officer, Chief Business Officer
  • Andreas Maetzel
    Senior Vice President, Medical
  • Edward Feener
    Chief Scientific Officer
  • Christopher Yea
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.